Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (21-30 of 303) with videos related to

Pageof 31
Sort By:
Cancer Research and Treatment|June 15, 2018
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or ErlotinibYoujin Kim, Se-Hoon Lee, Jin Seok Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2020
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Opinion on Biological Therapy|January 23, 2016
Pembrolizumab for the treatment of non-small cell lung cancerSung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, et al.
Clinical Nuclear Medicine|December 6, 2018
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk StratificationSeung Hwan Moon, Jong-Mu Sun, Jin Seok Ahn, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 13, 2024
Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapyJeong Yun Jang, Dongryul Oh, Jae Myoung Noh, et al.
Cancer Research and Treatment|January 3, 2023
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung CancerHyun Ae Jung, Sehhoon Park, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21Sung Hee Lim, Ji Yun Lee, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung CancerJang Ho Cho, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Review of Molecular Diagnostics|August 26, 2017
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancerBo Mi Ku, Jong-Mu Sun, Se-Hoon Lee, et al.
Translational Lung Cancer Research|October 19, 2023
Real-world clinical evidence of lazertinib use in acquired <i>EGFR</i> T790M mutated non-small cell lung cancerSehhoon Park, Hyun Ae Jung, Se-Hoon Lee, et al.
Pageof 31

Showing results (21-30 of 303) with videos related to

Sort By:
Pageof 31
Cancer Research and Treatment|June 15, 2018
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or ErlotinibYoujin Kim, Se-Hoon Lee, Jin Seok Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2020
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Opinion on Biological Therapy|January 23, 2016
Pembrolizumab for the treatment of non-small cell lung cancerSung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, et al.
Clinical Nuclear Medicine|December 6, 2018
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk StratificationSeung Hwan Moon, Jong-Mu Sun, Jin Seok Ahn, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 13, 2024
Prognostic impact of muscle mass loss in elderly patients with oesophageal cancer receiving neoadjuvant chemoradiation therapyJeong Yun Jang, Dongryul Oh, Jae Myoung Noh, et al.
Cancer Research and Treatment|January 3, 2023
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung CancerHyun Ae Jung, Sehhoon Park, Se-Hoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21Sung Hee Lim, Ji Yun Lee, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung CancerJang Ho Cho, Jong-Mu Sun, Se-Hoon Lee, et al.
Expert Review of Molecular Diagnostics|August 26, 2017
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancerBo Mi Ku, Jong-Mu Sun, Se-Hoon Lee, et al.
Translational Lung Cancer Research|October 19, 2023
Real-world clinical evidence of lazertinib use in acquired <i>EGFR</i> T790M mutated non-small cell lung cancerSehhoon Park, Hyun Ae Jung, Se-Hoon Lee, et al.
Pageof 31